Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03290534 · ClinicalTrials.gov registry record · Phase 2
Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet®
A Phase 2 study of Lung Cancer and Lung Cancer Stage II, sponsored by CivaTech Oncology.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT03290534 is a Phase 2 study of Lung Cancer and Lung Cancer Stage II that is actively recruiting participants, run by CivaTech Oncology. The registered enrollment target is 40 participants, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03290534, a Phase 2 study of Lung Cancer and Lung Cancer Stage II, is actively recruiting participants, sponsored by CivaTech Oncology.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a feasibility study to determine the usefulness of a brachytherapy device that utilizes active components (palladium-103) of standard devices in a novel configuration, which may benefit lung cancer patients by reducing the radiation dose to critical structures, such as the heart wall, while giving a therapeutic dose to diseased tissue, such as at a surgical margin.
Conditions Studied
Interventions
- DEVICE CivaSheet
Study Locations (1)
New York
- NYU Langone Health - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2019-03-13 |
| Est. Completion | 2027-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03290534
The ClinicalTrials.gov registry entry for NCT03290534 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (96% lower). The listed sponsor is CivaTech Oncology, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which CivaSheet is the first listed.
NCT03290534 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT03290534 about?
NCT03290534 is a clinical study titled "Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet®". This is a feasibility study to determine the usefulness of a brachytherapy device that utilizes active components (palladium-103) of standard devices in a novel configuration, which may benefit lung cancer patients by reducing the radiation dose to critical structures, such as the heart wall, while ...
What is the current status of trial NCT03290534?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2019-03-13. Estimated completion is 2027-12.
What conditions does trial NCT03290534 study?
This clinical trial studies the following conditions: Lung Cancer, Lung Cancer Stage II, Lung Cancer Stage I.
What interventions are being tested in trial NCT03290534?
The interventions under investigation include: CivaSheet (DEVICE).
Who is sponsoring clinical trial NCT03290534?
This trial is sponsored by CivaTech Oncology, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03290534 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Novel Treatment Combinations in Patients With Lung Cancer
RECRUITING · Phase 2
-
ATATcH Alternating Treatment Plans for Advanced Cancer
RECRUITING · Phase 2
-
A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury
RECRUITING · Phase 2
-
Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.